Skip to main content
TOPICS
Videos
Provider
Payer
Pharma
Consumer
Investor
RESOURCES
Events
Jobs
Learning Center
Webinars
White Papers
REGIONS
ANZ
ASIA
EMEA
Global Edition
MORE
About
Advertise
Contact
Privacy Policy
ANZ
ASIA
EMEA
Global Edition
Octave Bioscience
Octave Bioscience scores $30M for neurodegenerative disease offerings
By
Jessica Hagen
|
05:30 pm |
July 26, 2023
The multiple sclerosis-focused company will use the funds to speed up the company's commercialization efforts.